A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David Elsley – Cardiol Therapeutics

FULL DISCLOSURE: This is sponsored content for Cardiol Therapeutics.

Discover the major breakthrough at Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) as CEO David Elsley reveals the enrollment of their first patient in the pivotal Phase 3 MAVERIC trial for recurrent pericarditis. In this concise interview, Elsley discusses how their oral drug therapy aims to prevent new episodes of this debilitating heart condition, the impressive Phase 2 results showing significant pain reduction, and the potential timeline for market entry by mid-2026.

With trial sites at prestigious institutions like Mass General, Cleveland Clinic, and Mayo Clinic, and a market potential approaching $1 billion by 2028, investors won’t want to miss this significant development in cardiovascular medicine.


FULL DISCLOSURE: Cardiol Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cardiol Therapeutics. The author has been compensated to cover Cardiol Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Small Caps “Should Do Incredibly Well” In 2023 – With Chris Andrew of Clarmond Wealth

Joining us today on the Daily Dive is Chris Andrew, CEO of Clarmond Wealth. Chris...

Wednesday, January 25, 2023, 01:30:00 PM

Outlook On Copper & Gold In 2023 – With Joe Mazumdar

Joining us on the Daily Dive this afternoon is Joe Mazumdar, Editor, Analyst and Publisher...

Thursday, January 12, 2023, 01:31:22 PM

Are We On The Cusp Of A Precious Metals Rally? – The Daily Dive

Today on the Daily Dive, we see the return of Craig Hemke of TF Metals...

Tuesday, May 10, 2022, 01:30:00 PM

Why Gold’s Bull Run May Just Be Getting Started! | Peter Grandich

Peter Grandich takes us through some pretty controversial territory in this conversation, covering Trump’s attempted...

Sunday, July 27, 2025, 02:31:00 PM

Is $300 Oil Possible? – The Daily Dive

Joining us today on the Daily Dive is Ted Oakley, Managing Partner of Oxbow Advisors....

Wednesday, March 9, 2022, 01:30:00 PM